oral covalent BTK inhibitor

>80% BTK occupancy <5 mg (Ph. I dose esc.)

from fragment-based screen of 11k cmpds

Journal of Medicinal Chemistry

Takeda, San Diego, CA, USA

Structure of TAK-020

The Takeda covalent BTK inhibitor clinical candidate,┬áTAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: